Probi AB
STO:PROB

Watchlist Manager
Probi AB Logo
Probi AB
STO:PROB
Watchlist
Price: 348 SEK Market Closed
Market Cap: 4B SEK
Section:
 

Relative Value

The Relative Value of one PROB stock under the Base Case scenario is 238.76 SEK. Compared to the current market price of 348 SEK, Probi AB is Overvalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PROB Relative Value
Base Case
238.76 SEK
Overvaluation 31%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.3
P/S
P/S
Price to Sales
6.3
vs History
26
vs Industry
54
Median 3Y
4.1
Median 5Y
5.8
Industry
7.9
Forward
6.2
More Details
364.3
P/E
P/E
Price to Earnings
364.3
vs History
1
vs Industry
0
Median 3Y
165.6
Median 5Y
60.8
Industry
23.7
Forward
245.5
More Details
30
P/OCF
P/OCF
Price to OCF
30
vs History
25
vs Industry
6
Median 3Y
29.7
Median 5Y
28.2
Industry
22
More Details
68.6
P/FCFE
P/FCFE
Price to FCFE
68.6
vs History
19
vs Industry
3
Median 3Y
68.6
Median 5Y
54.8
Industry
23.8
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
30
vs Industry
31
Median 3Y
1.8
Median 5Y
2.9
Industry
3.3
More Details
5.8
EV/S
EV/S
Enterprise Value to Sales
5.8
vs History
28
vs Industry
47
Median 3Y
3.6
Median 5Y
5.6
Industry
8.3
Forward
5.7
More Details
17.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
17.6
vs History
6
vs Industry
28
Median 3Y
11.1
Median 5Y
13.9
Industry
10.1
More Details
35.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
35.3
vs History
1
vs Industry
4
Median 3Y
26.5
Median 5Y
23.3
Industry
6.4
Forward
31.9
More Details
1 194.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
1 194.9
vs History
1
vs Industry
0
Median 3Y
223.2
Median 5Y
43.7
Industry
7
Forward
313.4
More Details
27.8
EV/OCF
EV/OCF
Enterprise Value to OCF
27.8
vs History
26
vs Industry
6
Median 3Y
27.5
Median 5Y
26.7
Industry
8.3
More Details
48.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
48.2
vs History
23
vs Industry
3
Median 3Y
48.2
Median 5Y
45.5
Industry
6.5
More Details
3.2
EV/IC
EV/IC
Enterprise Value to IC
3.2
vs History
30
vs Industry
38
Median 3Y
1.9
Median 5Y
3.2
Industry
5.7
More Details

Multiples Across Competitors

PROB Competitors Multiples
Probi AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Probi AB
STO:PROB
4B SEK 6.3 364.3 35.3 1 194.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 770 229.5 -160 504.9 -194 904.1 -192 680.1
US
Abbvie Inc
NYSE:ABBV
395.3B USD 6.6 168.4 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
175.8B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
147.5B USD 5.1 18.2 12.2 12.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.6B USD 9.9 31.4 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.1 -532.3 -579.6 -564.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.2 16.3 18.5
AU
CSL Ltd
ASX:CSL
84.7B AUD 3.6 18.7 12.6 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD 16.1 1 183.4 155.3 188.4
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.4 34 58.6 60.2
P/S Multiple
Revenue Growth P/S to Growth
SE
Probi AB
STO:PROB
Average P/S: 3 070 217.1
6.3
5%
1.3
FR
Pharnext SCA
OTC:PNEXF
33 770 229.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 086.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
46%
0.3
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
SE
Probi AB
STO:PROB
Average P/E: 206.7
364.3
40%
9.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 504.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 183.4
N/A N/A
NL
argenx SE
XBRU:ARGX
34
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Probi AB
STO:PROB
Average EV/EBITDA: 38.7
35.3
15%
2.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 904.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
7%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.6
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Probi AB
STO:PROB
Average EV/EBIT: 172.8
1 194.9
66%
18.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 680.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.4
N/A N/A
NL
argenx SE
XBRU:ARGX
60.2
N/A N/A

See Also

Summary
PROB intrinsic value, competitors valuation, and company profile.
DCF Valuation
PROB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PROB stock valuation using valuation multiples.
Wall Street Estimates
PROB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PROB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.